KRAS and cancer: EFR3A-PI4KA interaction on the PM has been implicated in many KRAS-dependent tumors, and treatments with PI4KA inhibitors along with KRAS inhibitors, or MAPK and PI3K inhibitors have proved to improve efficacy in cancer cell growth inhibition44.